Ovarian Serous Adenocarcinoma clinical trials at UC Davis

1 research study open to eligible people

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
“Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”
open to eligible females ages 18 years and up
Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with newly diagnosed advanced ovarian cancer who have undergone optimal debulking.
Sacramento, California and other locations

Last updated: December 2023

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery